Raising €2 million for AI-driven devices focused on cardiovascular imaging, AIATELLA secures funding.
AIATELLA Secures Funding for Revolutionary Cardiovascular Imaging Technology
Finnish medtech startup AIATELLA has secured €2 million in seed funding to advance its AI-powered cardiovascular imaging technology. This investment, led by Helsinki-based Nordic Science Investments, also includes participation from Specialist VC, Harjavalta Ventures, Business Finland, and a syndicate of angel investors.
The technology, which uses images from MRI, CT, and ultrasound to analyse vascular imaging, has the potential to streamline workflow and provide standardised expert-level measurements. It is designed for early cardiovascular disease detection during regular health checkups, making it accessible in diverse settings such as occupational health, insurance assessments, mobile blood banks, vaccination drives, and disease prevention programs.
AIATELLA's technology automates the analysis of images, reducing the time spent by specialists on routine tasks. This allows healthcare professionals to focus more on patient care and decision-making, potentially leading to faster diagnoses and better treatment outcomes.
The technology can detect and quantify abnormalities and changes over time in at-risk patients. Given that cardiovascular diseases are the leading cause of death globally, but up to 80% of these deaths are preventable through early detection and treatment, AIATELLA's preventative screening services aim to make early detection cost-effective for millions of people.
Acknowledging and working to close the gender and ethnicity health gap is a key priority for AIATELLA. The company aims to scale screening to gain insights into differences in how cardiovascular diseases present and progress between different ethnicities and sexes. This could lead to more personalised and effective treatments.
While specific details about AIATELLA's portable screening technology and its direct impact on detecting carotid artery narrowing are not explicitly mentioned, the company's overall focus on AI-driven cardiovascular imaging suggests a potential for significant advancements in early disease detection. AIATELLA's technology has already been used in partnership with medical professionals in Finland and the UK, helping identify tens of individuals potentially at risk.
The company is currently in medical approval processes in several countries across Europe and North America. Kaspar Hanni, Partner at Specialist VC, emphasized the importance of accessible preventative technology in today's healthcare systems, stating that AIATELLA's technology can play a crucial role in improving early detection and prevention of cardiovascular diseases.
- AIATELLA's AI-powered cardiovascular imaging technology, which is currently undergoing clinical trials, will enable early detection of cardiovascular diseases during routine health checkups, making it accessible in diverse settings like health-and-wellness programs, occupational health, and mobile blood banks.
- By automating the analysis of images from MRI, CT, and ultrasound, AIATELLA's technology is not only streamlining workflow but also allowing healthcare professionals to focus more on patient care and clinical decision-making, leading to faster diagnoses and potentially better treatment outcomes.
- Given the global significance of cardiovascular diseases as the leading cause of death, AIATELLA's goal is to make preventative screening services cost-effective for millions of people, thereby reducing the number of preventable deaths.
- In line with their commitment to addressing the gender and ethnicity health gap, AIATELLA aims to scale their screening services to gain insights into the differences in how cardiovascular diseases present and progress among various ethnicities and sexes, ultimately leading to more personalized and effective treatments in digital health.
